Radiprodil

Radiprodil is an investigational drug with demonstrated potential for treating seizures associated with GRIN-related neurodevelopmental disorders, a condition caused by gain-of-function mutations in the GRIN2B gene. Clinical trials have shown that radiprodil is well-tolerated and significantly reduces seizure frequency in affected individuals. It is a selective, potent negative allosteric modulator of the NR2B subunit of the NMDA receptor, which helps to control overactive brain activity characteristic of these disorders. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include RGH-896, (1-Piperidineacetamide, N-(2 and 3-dihydro-2-oxo-6-benzoxazolyl)-4-[(4-fluorophenyl)methyl]-alpha-oxo-). Its PubChem CID is 10200813.

CAS No 496054-87-6
Molecular Formula C21H20FN3O4
Molecular Weight 397.4 g/mol
Synonyms 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide

Frequently Asked Questions